CMPCPS 001
Alternative Names: CMP-CPS-001Latest Information Update: 13 Jan 2025
Price :
$50 *
At a glance
- Originator CAMP4 Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action Carbamoyl phosphate synthase (ammonia) expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inborn urea cycle disorders
Most Recent Events
- 07 Jan 2025 Interim adverse events data from a phase-I trial in Inborn urea cycle disorders released by CAMP4 Therapeutics
- 07 Jan 2025 CAMP4 Therapeutics plans a phase-II/III trial for Inborn urea cycle disorders in the year 2026
- 21 Nov 2024 CAMP4 plans a phase II/III registrational trial for Urea cycle disorders